|
|
|
|
| |
|
Newsletter Sponsor
|
|
White Paper: FDA 483s and Non-Compliance in Pharma
The United States Food and Drug Administration (FDA) has the authority to inspect pharmaceutical companies that manufacture FDA-regulated products at any time, and write down their observations on Form FDA 483, commonly abbreviated to “483”. Form 483s are very important to FDA-regulated companies, regardless of how many, if any, they have received. A single 483 tells a company exactly which areas to improve - or to correct - to remain compliant (and therefore operational). Download this white paper to learn more about FDA 483’s, drug production, compliance and QC.
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
More Products
|
|
|
|
FlexAct Configurable Bioprocess Solution Learn More
Pharmaceutical Manufacturing and Drug Development Services Learn More
SWELSTAR Pregelatinized Starch NF WB-1(Wet binder) Learn More
|
|
|
|
|
| |
|
Events |
|
|
| |
|
|
IFPAC-2024
Washington, D.C. – 03/03/2024
Join industry leaders, regulators, researchers, and solution providers from across the globe for in-depth discussions on the latest trends, ...
event details » |
 |
|
|
|
|
 |
|
|
